Insider Buying: GSK (LON:GSK) Insider Purchases £73,981.46 in Stock

GSK plc (LON:GSK) insider Wendy Becker purchased 3,334 shares of the stock in a transaction on Friday, February 20th. The stock was acquired at an average price of GBX 2,219 per share, with a total value of £73,981.46.

Wendy Becker also recently made the following trade(s):

• On Friday, December 19th, Wendy Becker acquired 441 shares of GSK stock. The shares were bought at an average cost of GBX 1,809 per share, with a total value of £7,977.69.

GSK Trading Down 0.1%

Shares of LON:GSK opened at GBX 2,223.16 on Monday. The firm has a market cap of £89.70 billion, a price-to-earnings ratio of 16.72, a PEG ratio of 1.24 and a beta of 0.31. GSK plc has a 12 month low of GBX 1,242.50 and a 12 month high of GBX 2,282. The company’s fifty day simple moving average is GBX 1,923 and its 200 day simple moving average is GBX 1,726.90. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64.

GSK (LON:GSK) last released its earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, research analysts forecast that GSK plc will post 175.980975 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on GSK. Citigroup raised their price target on shares of GSK from GBX 1,900 to GBX 2,250 and gave the stock a “buy” rating in a research note on Monday, February 9th. Berenberg Bank boosted their price objective on shares of GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a research report on Monday, November 24th. Shore Capital Group restated a “buy” rating and set a GBX 2,300 target price on shares of GSK in a report on Wednesday, February 4th. UBS Group reiterated a “neutral” rating and issued a GBX 1,940 price target on shares of GSK in a research note on Friday, January 23rd. Finally, JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research report on Wednesday, January 7th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of GBX 1,917.86.

Key GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Investor confidence boost — IBD upgraded GSK’s ADR, a technical/fundamental endorsement that can attract momentum and retail buying. GSK ADR earns IBD stock rating upgrade
• Positive Sentiment: Insider buying — independent director Wendy Becker purchased 3,334 shares at ~GBX 2,219, signaling management/board conviction. Insider purchases often support sentiment. GSK Director Wendy Becker Increases Stake with Share Purchase
• Positive Sentiment: Ongoing buybacks — GSK repurchased 470,000 shares (~£10.5m) recently, modestly supporting EPS and indicating capital return. GSK lifts treasury stake with latest £10.5m share buyback
• Positive Sentiment: Clinical/commercial upside — a real‑world study reported AREXVY (RSV vaccine) is associated with lower risks of heart attack, stroke and severe COPD/asthma exacerbations, which could bolster uptake and long‑term revenue. GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks
• Positive Sentiment: R&D partnerships — GSK struck multi‑year collaborations with Jackson Laboratory / NYSCF to advance human cellular models and neurodegenerative research, strengthening its pipeline in high‑value areas. These are longer‑term positives for drug discovery. GSK strikes 5-year deal with Jackson Laboratory
• Neutral Sentiment: Trading activity — options activity has spiked on NYSE listings, indicating speculative interest and short‑term volatility rather than a directional fundamental change. GSK Sees Options Surge in NYSE Composite
• Neutral Sentiment: Analyst/market discussion — some market pieces question whether GSK’s recent rally limits upside, which can cool momentum even amid positive fundamentals. Is It Too Late To Consider GSK After Its Strong Share Price Rally?
• Negative Sentiment: Insider selling — former CEO Luke Miels sold 15,579 shares recently; large director/exec sales can weigh on sentiment even if they’re for personal reasons. Luke Miels Sells 15,579 Shares of GSK Stock

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.